BioNTech SE

BMV:BNTX N Stock Report

Market Cap: Mex$552.1b

BioNTech Valuation

Is BNTX N undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BNTX N when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate BNTX N's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate BNTX N's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BNTX N?

Key metric: As BNTX N is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for BNTX N. This is calculated by dividing BNTX N's market cap by their current revenue.
What is BNTX N's PS Ratio?
PS Ratio8.7x
Sales€3.04b
Market Cap€26.31b

Price to Sales Ratio vs Peers

How does BNTX N's PS Ratio compare to its peers?

The above table shows the PS ratio for BNTX N vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average14x
MRNA Moderna
3x5.8%US$15.5b
BIIB Biogen
2.3x1.3%US$21.7b
603392 Beijing Wantai Biological Pharmacy Enterprise
37.1x60.9%CN¥92.5b
A068270 Celltrion
13.7x26.0%₩40.1t
BNTX N BioNTech
8.7x2.8%Mex$27.4b

Price-To-Sales vs Peers: BNTX N is good value based on its Price-To-Sales Ratio (8.7x) compared to the peer average (14x).

Price to Sales Ratio vs Industry

How does BNTX N's PS Ratio compare vs other companies in the Global Biotechs Industry?

233 CompaniesPrice / SalesEstimated GrowthMarket Cap
BNTX N 8.7xIndustry Avg. 8.8xNo. of Companies233PS01224364860+
233 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: BNTX N is good value based on its Price-To-Sales Ratio (8.7x) compared to the Global Biotechs industry average (8.8x).

Price to Sales Ratio vs Fair Ratio

What is BNTX N's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BNTX N PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio8.7x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate BNTX N's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BNTX N forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentMex$2,268.00
Mex$2,762.44
+21.8%
10.8%Mex$3,451.13Mex$2,429.39n/a19
Dec ’25Mex$2,469.60
Mex$2,789.64
+13.0%
9.6%Mex$3,527.83Mex$2,489.90n/a18
Nov ’25Mex$2,250.00
Mex$2,616.56
+16.3%
17.1%Mex$3,460.54Mex$1,808.88n/a18
Oct ’25Mex$2,349.99
Mex$2,404.75
+2.3%
19.6%Mex$3,316.58Mex$1,648.59n/a18
Sep ’25Mex$1,755.59
Mex$2,186.34
+24.5%
20.4%Mex$3,428.71Mex$1,704.33n/a18
Aug ’25Mex$1,612.00
Mex$2,095.27
+30.0%
20.3%Mex$3,211.76Mex$1,692.04n/a18
Jul ’25n/a
Mex$2,029.53
0%
20.2%Mex$3,127.99Mex$1,637.31n/a18
Jun ’25n/a
Mex$1,897.73
0%
20.4%Mex$2,921.12Mex$1,532.47n/a18
May ’25n/a
Mex$1,948.12
0%
20.7%Mex$2,878.11Mex$1,521.37n/a18
Apr ’25n/a
Mex$1,943.30
0%
23.6%Mex$3,097.38Mex$1,488.58n/a18
Mar ’25Mex$1,598.00
Mex$2,157.75
+35.0%
22.5%Mex$3,206.78Mex$1,687.21n/a17
Feb ’25Mex$1,599.00
Mex$2,183.28
+36.5%
22.4%Mex$3,221.25Mex$1,694.82n/a16
Jan ’25Mex$1,779.00
Mex$2,255.38
+26.8%
21.0%Mex$3,161.27Mex$1,708.08n/a16
Dec ’24Mex$1,679.00
Mex$2,316.17
+37.9%
23.0%Mex$3,421.07Mex$1,704.72Mex$2,469.6017
Nov ’24Mex$1,700.00
Mex$2,482.83
+46.0%
23.1%Mex$3,443.12Mex$1,813.59Mex$2,250.0017
Oct ’24n/a
Mex$2,547.89
0%
22.9%Mex$3,430.18Mex$1,729.28Mex$2,349.9916
Sep ’24Mex$2,090.00
Mex$2,642.56
+26.4%
26.1%Mex$4,221.20Mex$1,681.27Mex$1,755.5917
Aug ’24Mex$1,776.00
Mex$2,706.51
+52.4%
24.7%Mex$4,196.10Mex$1,819.27Mex$1,612.0017
Jul ’24Mex$1,846.50
Mex$2,833.95
+53.5%
23.1%Mex$4,257.54Mex$1,845.91n/a16
Jun ’24Mex$1,842.00
Mex$2,828.45
+53.6%
23.4%Mex$4,309.50Mex$1,868.43n/a17
May ’24n/a
Mex$3,196.27
0%
23.7%Mex$4,720.76Mex$2,294.86n/a17
Apr ’24n/a
Mex$3,315.15
0%
22.2%Mex$4,691.92Mex$2,357.14n/a16
Mar ’24Mex$2,482.00
Mex$3,749.96
+51.1%
23.4%Mex$5,410.03Mex$2,570.63Mex$1,598.0015
Feb ’24Mex$2,630.00
Mex$3,946.72
+50.1%
23.5%Mex$5,698.09Mex$2,716.67Mex$1,599.0015
Jan ’24Mex$3,005.80
Mex$4,224.52
+40.5%
23.2%Mex$6,498.75Mex$3,016.98Mex$1,779.0015
Dec ’23Mex$3,235.00
Mex$4,091.06
+26.5%
22.4%Mex$6,198.42Mex$2,892.27Mex$1,679.0016

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 11:56
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BioNTech SE is covered by 29 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
Zhiqiang ShuBerenberg
Etzer DaroutBMO Capital Markets Equity Research